Search Results - "Jahn, Thomas M."

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia by FURMAN, Richard R, SHARMAN, Jeff P, GHIA, Paolo, ERADAT, Herbert, ERVIN, Thomas, LAMANNA, Nicole, COIFFIER, Bertrand, PETTITT, Andrew R, SHUO MA, STILGENBAUER, Stephan, CRAMER, Paula, AIELLO, Maria, COUTRE, Steven E, JOHNSON, Dave M, MILLER, Langdon L, LI, Daniel, JAHN, Thomas M, DANSEY, Roger D, HALLEK, Michael, O'BRIEN, Susan M, CHESON, Bruce D, PAGEL, John M, HILLMEN, Peter, BARRIENTOS, Jacqueline C, ZELENETZ, Andrew D, KIPPS, Thomas J, FLINN, Ian

Get full text

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia by Furman, Richard R, Sharman, Jeff P, Coutre, Steven E, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M, Miller, Langdon L, Li, Daniel, Jahn, Thomas M, Dansey, Roger D, Hallek, Michael, O'Brien, Susan M

“…A placebo-controlled study of idelalisib in patients with relapsed chronic lymphocytic leukemia who were receiving rituximab was stopped early because of…”
Get full text

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia by Brown, Jennifer R., Byrd, John C., Coutre, Steven E., Benson, Don M., Flinn, Ian W., Wagner-Johnston, Nina D., Spurgeon, Stephen E., Kahl, Brad S., Bello, Celeste, Webb, Heather K., Johnson, Dave M., Peterman, Sissy, Li, Daniel, Jahn, Thomas M., Lannutti, Brian J., Ulrich, Roger G., Yu, Albert S., Miller, Langdon L., Furman, Richard R.

“…In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3Kδ, was evaluated in 54 patients with relapsed/refractory…”
Get full text

Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia by Pagel, John M, Coutre, Steven E, Furman, Richard R, Sharman, Jeff P, Cheson, Bruce D, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W, Ghia, Paolo, Eradat, Herbert A, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew, Li, Xiaoming, Jahn, Thomas M, O’Brien, Susan M, Hallek, Michael J

Get full text

5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B) by Brown, Jennifer R, Jahn, Thomas M, Furman, Richard R, Leonard, John P, Spurgeon, Stephen E, Byrd, John C, Benson, Don M, Coutre, Steven E, Wagner-Johnston, Nina D, Flinn, Ian W, Kahl, Brad S, Schreeder, Marshall T, de Vos, Sven, Holes, Leanne M, Peterman, Harriet (Sissy), Johnson, Dave M, Miller, Langdon L

Get full text

Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer by Wainberg, Zev, Kang, Yoon-Koo, Lee, Keun-Wook, Kim, Seung Tae, Chao, Joseph, Catenacci, Daniel, Oh, Sung Yong, Soares, Heloisa P., Selfridge, J. Eva, Cha, Yongjun, Skeel, Roland T., Kim, Hyung-Don, Tran, Anh, Moesta, Achim, Dela Cruz, Tracy, Singhal, Anil, Jahn, Thomas M., Dayyani, Farshid

“…Abstract Background: The ecto-ATPase CD39 is the rate-limiting enzyme in the adenosine pathway that plays an important immune regulatory role. Preclinically,…”
Get full text

Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) by Barrientos, Jacqueline C., Coutre, Steven E., de Vos, Sven, Wagner-Johnston, Nina D., Flinn, Ian W., Sharman, Jeff P., Schreeder, Marshall T., Boyd, Thomas E, Rai, Kanti R., Leonard, John P., Kim, Yeonhee, Viggiano, Anthony, Jahn, Thomas M., Furman, Richard R.

“…BACKGROUND: PI3Kδ signaling is critical for the proliferation and survival as well as for homing and tissue retention of malignant B cells. Idelalisib is a…”
Get full text

Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) by Furman, Richard R., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Flinn, Ian W., Sharman, Jeff P., Boyd, Thomas E, Fowler, Nathan, Leonard, John P., Rai, Kanti R., Kim, Yeonhee, Viggiano, Anthony, Jahn, Thomas M., Coutre, Steven E.

“…Introduction: PI3Kδ signaling is critical for the proliferation, survival and homing/tissue retention of malignant B cells. Idelalisib is a first-in-class,…”
Get full text

A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia by Furman, Richard R., De Vos, Sven, Leonard, John P., Barrientos, Jacqueline C., Schreeder, Marshall T., Flinn, Ian W., Sharman, Jeff P., Boyd, Thomas, Fowler, Nathan, Rai, Kanti R., Kim, Yeonhee, Holes, Leanne M., Dansey, Roger, Jahn, Thomas M., Coutre, Steven E.

“…PI3Kδ signaling is critical for the proliferation and survival as well as for homing and tissue retention of malignant B cells. Idelalisib is a first-in-class,…”
Get full text

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors by Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Hallek, Michael, Coiffier, Bertrand, O’Brien, Susan, Tausch, Eugen, Kreuzer, Karl-Anton, Jiang, Wendy, Lazarov, Mirella, Li, Daniel, Jahn, Thomas M., Stilgenbauer, Stephan

“…BACKGROUND: There is high unmet need in frail pts with relapsed CLL, particularly in those characterized by adverse prognostic factors such as presence of…”
Get full text

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL) by Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Hallek, Michael, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D., O'Brien, Susan M.

“…Idelalisib (IDELA) is a first-in-class, selective, oral inhibitor of PI3Kδ that reduces proliferation, enhances apoptosis, and inhibits homing and retention of…”
Get full text

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study by Coutre, Steven E., Leonard, John P., Furman, Richard R., Barrientos, Jacqueline C., de Vos, Sven, Flinn, Ian W., Schreeder, Marshall T., Wagner-Johnston, Nina D., Sharman, Jeff, Boyd, Thomas E., Fowler, Nathan H, Holes, Leanne M., Lannutti, Brian J., Johnson, Dave M., Miller, Langdon L, Jahn, Thomas M.

“…Abstract 191 PI3Kdelta drives proliferation and survival in malignant B-cells. GS-1101 is an orally bioavailable, small-molecule inhibitor of PI3Kdelta that…”
Get full text

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study by Fowler, Nathan H, de Vos, Sven, Schreeder, Marshall T., Leonard, John P., Flinn, Ian W., Coutre, Steve, Wagner-Johnston, Nina D., Sharman, Jeff, Boccia, Ralph V., Barrientos, Jacqueline C., Boyd, Thomas E., Holes, Leanne M., Lannutti, Brian J., Johnson, David, Jahn, Thomas M., Miller, Langdon L, Godfrey, Wayne R

“…Abstract 3645 PI3Kδ drives proliferation and survival in malignant B-cells. GS-1101 is an orally bioavailable, small-molecule inhibitor of PI3Kδ that has shown…”
Get full text

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL) by de Vos, Sven, Schreeder, Marshall T., Flinn, Ian W., Coutre, Steven E., Leonard, John P., Wagner-Johnston, Nina D., Fowler, Nathan H., Boccia, Ralph V., Barrientos, Jaqueline C., Boyd, Thomas, Sharman, Jeff, Holes, Leanne, Lannutti, Brian, Johnson, Dave M., Jahn, Thomas M., Miller, Langdon L

“…Abstract 2699 PI3Kδ is expressed in cells of hematopoietic origin where it regulates survival and proliferation of normal and malignant B-cells. CAL-101…”
Get full text

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) by Sharman, Jeff, de Vos, Sven, Leonard, John P., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Schreeder, Marshall T., Barrientos, Jaqueline C., Wagner-Johnston, Nina D., Boyd, Thomas, Fowler, Nathan H., Holes, Leanne, Lannutti, Brian, Johnson, David, Jahn, Thomas M., Miller, Langdon L

“…Abstract 1787 PI3Kδ is expressed in cells of hematopoietic origin where it regulates survival and proliferation of normal and malignant B-cells. CAL-101…”
Get full text